Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Metformin/Gliclazide Fixed Combination vs Individual Tablets
NCT03467945Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2018
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gliclazide + metformin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration, Maximum Observed Plasma Concentration and 1 more. Started Feb 2018; status: completed.
02
Drugs
gliclazide + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03467945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03467945.